ClinicalTrials.gg
CompletedNCT00250250Updated May 20, 2011

An Open-Label, Multi-centre, Phase III Study of Local Tolerability of ZOMACTON 10MG

A Phase 3 interventional study of ZOMACTON in Turner's Syndrome, sponsored by Ferring Pharmaceuticals. Completed at 6 sites in 3 countries. Open to participants aged 3 Years to 17 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2011-05-20.

Sponsored by Ferring Pharmaceuticals · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
27
Allocation
Randomized
Ages
3 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 14 studies testing Human Growth Hormone in Turner Syndrome — none open to participants now, none under way, none of them phase 3. Human Growth Hormone · Turner Syndrome.

Enrollment
13th of 14
27 · median 108
Started
2005
with 2 others
Phase 3
6 of 14
none open now
Registered
4th of 14
by date
Lead sponsor
1 of 14
Ferring Pharmaceuticals

Among the 14 studies testing Human Growth Hormone in Turner Syndrome, this one is the 13th largest by enrollment, is one of 3 that started in 2005, is one of 6 in phase 3, and was the 4th registered.

Turner Syndrome

125 studies on the registry are indexed under Turner Syndrome; 33 are open to participants now.

Browse Turner Syndrome studies →

Open to participants now

None of the 14 studies testing Human Growth Hormone in Turner Syndrome is open now. The open studies under Turner Syndrome, anywhere →

About Human Growth Hormone

Human Growth Hormone: first FDA approval 1986 (HUMATROPE), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 25 Turner Syndrome studies recruiting now, 8 (32%) set no upper age limit and 14 (56%) stop at 75 or younger; 15 take children under 18; 5 take healthy volunteers.

This study: 3 Years to 17 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 14 studies testing Human Growth Hormone in Turner Syndrome as a file.
02

Study summary

Children with growth failure due to inadequate secretion of growth hormone or growth retardation due to Turner's syndrome are individually dosed and treated for 12 weeks

Read the detailed description

Ferring Pharmaceuticals A/S has developed a new ZOMACTON 10 mg formulation. The formulation provides a higher concentration and thereby a smaller volume to be administered. ZomaJet Vision X is a needle-free injection system. It sends a thin jet of ZOMACTON through the skin and into the subcutaneous tissue without the use of a needle. The mode of administration is referred to as "transjection". By use of ZomaJet Vision X, both transjection and reconstitution of ZOMACTON 10 mg can be done without using a needle. The rationale of the study is to describe the local tolerability of the new ZOMACTON 10 mg administered by ZomaJet Vision X.

03

Conditions studied

  • Turner's Syndrome

Browse trials for

04

Who can participate

Ages eligible
3 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Subjects between the ages of 3 and 17 years (both inclusive) with growth failure due to inadequate secretion of growth hormone or growth retardation due to Turner's syndrome. Subjects have for a minimum of 6 months prior to study enrolment been receiving growth hormone therapy

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
27 participants (actual)

Interventions

06

What researchers measure

Primary outcomes

  1. To assess the local tolerability of an individualised dose of ZOMACTON 10 mg administered by ZomaJet Vision X

07

Study locations

6 sites
  • Faculty Hospital Olomouc, Children's Clinic, Endocrinology Outpatient Department, I.P.Pavlova str. 6,
    Olomouc, 775 20, Czech Republic
  • Faculty Hospital Kralovske Vinohrady, Children's Clinic, Vinohradska str. 159
    Prague 10, 100 81, Czech Republic
  • Masaryk Hospital Usti nad Labem, Children's Clinic, Building D2, Endocrinology Outpatient Department, Socialni pece 12a
    Usti nad Labem, 401 13, Czech Republic
  • Centre d'Endocrinologie Pediatrique, 25 rue Boudet
    Bordeaux, 33000, France
  • Service de Pédiatrie, Groupe Hospitalier du Havre, 55 bis, rue Gustave Flaubert
    Le Havre cedex, 76083, France
  • Vu medisch centrum, Paediatrics, De Boelelaan 1117, PO Box 7057
    Amsterdam, 10007 MB, Netherlands
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2005, a primary completion of Mar 2006 and a completion of Aug 2006. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 7, 2005
First posted
Nov 8, 2005
Start
Oct 2005
Primary completionActual
Mar 2006
CompletionActual
Aug 2006
Last update
May 20, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 20, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00250250
First posted
Nov 8, 2005
Start date
Oct 2005
Primary completion
Mar 2006
Completion
Aug 2006
Last update
May 20, 2011

Study contacts

Clinical Development Support
study director · Ferring Pharmaceuticals

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Human Growth Hormone

Start the discussion